Newsroom

university of washington’s baker lab and google deepmind redefine protein science, paving the way for ai-driven biotherapeutics victoria, british columbia (canada), october 10, 2024 – immunoprecise antibodies ltd. (the “company” or “ipa”) (nasdaq: ipa), an ai-driven biotherapeutic research and technology company, today celebrates the recent nobel prize in chemistry awarded to david baker of the university of washington, seattle, wa, usa, "for computational protein design," and jointly to demis hassabis and john m. jumper of google deepmind, london, uk, "for protein structure prediction." this accolade highlights the vital role of computational tools and ai in advancing our understanding of protein structures—principles that are central to ipa’s research initiatives. these achievements validate the methodologies that underpin ipa’s proprietary foundation ai model, lensai, which leverages similar computational and ai approaches to innovate drug discovery. "as ipa continues to enhance lensai, our proprietary ai platform, we remain committed to leveraging cutting-edge technologies to unravel complex protein interactions. the nobel prize recognition of alphafold underscores the growing importance of ai in scientific breakthroughs. at immunoprecise antibodies, we're dedicated to integrating advanced ai technologies into our workflows, which not only amplifies our capabilities in drug development but also aligns with our mission to pioneer innovative biotherapeutic solutions," said dr. jennifer bath, ceo of immunoprecise antibodies. at ipa, the integration of alphafold, an open-access ai tool developed by google deepmind, into our drug discovery processes has revolutionized how we approach complex biological challenges. by leveraging alphafold's freely available protein structure predictions, ipa enhances the design and optimization of antibodies, making significant strides in developing treatments for diseases that were previously deemed intractable. “our hyft technology amplifies the power of alphafold and other foundational ai models by providing deeper biological context. hyft identifies key functional and structural motifs within protein sequences, enhancing the precision of alphafold's predictions and extending its application in drug discovery, said dr. van hyfte, head of innovation at biostrand. “this combination enables us to push the boundaries of what’s possible in biotherapeutic development, accelerating the path from prediction to solution.” for a deeper dive into alphafold's impact on drug discovery and its integration into ipa's technology stack, explore their subsidiary, biostrand's, blog post: explained: a brief look into alphafold 2. looking ahead, ipa is keen to expand partnerships within academia and industry to further explore ai's potential in developing novel therapies. ipa invites interested parties to join in advancing the application of lensai, aiming for a future where diseases are not merely treated but understood and prevented. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. the company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges. ipa has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). investor relations contact kirsten beduya quantum media group, llc kirsten@quantum-corp.com forward-looking statement this press release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “expects” “estimates”, “intends”, “anticipates” or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “would”, “might” or “will” be taken, occur or be achieved. forward–looking statements include, but are not limited to, statements regarding computational and ai approaches to innovate drug discovery. . although the company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. our actual future results may be materially different from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions and the impact of general economic, industry or political conditions in the united states, canada or internationally. you should also consult our quarterly and annual filings with the canadian and u.s. securities commissions for additional information on risks and uncertainties. these forward–looking statements speak only as of the date of this press release and the company undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future. forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual report on form 20-f for the year ended april 30, 2024 (which may be viewed on the company’s sedar+ profile at www.sedar.ca and edgar profile at www.sec.gov/edgar). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking statements contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source: immunoprecise antibodies ltd.

victoria, british columbia, november 27, 2023 - immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, is pleased to announce important board of director changes and upcoming financial reporting activities. new board chairman mitch levine joined the board of directors of ipa at ipa’s recent annual general meeting and has been appointed as chairman of the board, bringing a wealth of experience from the life sciences industry and financial strategy, particularly in nasdaq market operations. as ceo and chairman of smarthealth dx since 2022, levine has focused the company’s strategy, operational efficiency, and boosted corporate value. at oncocyte, he drove significant growth as cfo from 2017 to 2022, overseeing all financial operations of the company, managing capital raises, navigating nasdaq complexities, and leading major acquisitions and a key licensing deal in china. his capital markets expertise was widely recognized as founder and managing member of enable capital management, llc, where for 17 years they provided growth capital to small- and mid-sized public companies, many traded on nasdaq. his background also includes a foundational role at the shemano group, a san francisco-based investment bank focused on technology and life sciences sectors. dr. jennifer bath, ceo of immunoprecise antibodies, lauds levine’s combination of life sciences and financial acumen as invaluable for ipa. his guidance is expected to be crucial for ipa's innovative growth, particularly in antibody discovery and development, and to further establish ipa as a leader in the biotech industry. “we anticipate his guidance in financial strategies and market dynamics to be a significant asset in driving ipa's innovative growth and expansion, especially as we progress our cutting-edge biotechnologies like hyft® and lensai™.” remuneration and nomination committee chairman chris buyse is currently the chairman of the remuneration and nomination committee, effective october 2, 2023. mr. buyse brings both experience with nasdaq traded life science companies as well as pharmaceutical industry experience. he is currently a board member and chairman of the audit committee of inventiva sa, a dual-listed company on euronext paris and nasdaq, and a board member and member of the audit committee of hyloris pharmaceuticals, a company listed on euronext brussels. new audit committee chairman additionally, ipa is pleased to announce the appointment of dirk witters as the new chairman of the audit committee, effective november 15, 2023. mr. witters brings a strong background in finance and auditing, having previously served as executive partner in a corporate finance boutique and was advisor to the founder of new rhein healthcare investors, a private equity investment firm focused on healthcare therapeutics and medical devices, where he assisted with the capital raise of the second investment fund. mr. witters also spent 20+ years with kbc group’s corporate and investment banking division where he gained experience in business development, strategy execution, advisory and corporate finance. the appointment of mr. witters as chairman of ipa’s audit committee underscores ipa's commitment to maintaining the highest standards of financial oversight and corporate governance. "we at ipa are thrilled to embark on this exciting new chapter with the support of our shareholders and stakeholders, guided by our esteemed leadership team. the appointment of mitch levine as our chairman, along with chris buyse as chairman of the remuneration and nomination committee, and dirk witters as the new chairman of the audit committee, marks a significant milestone for our company, stated dr. bath.” their combined expertise in the life sciences sector, financial strategy, and corporate governance, especially in nasdaq-listed environments, not only reflects the strong backing we have from our shareholders but also reinforces our commitment to excellence and innovation in biotechnology. we believe that their leadership and insights will be instrumental in steering ipa towards groundbreaking advancements and sustained growth in the industry." upcoming second quarter 2023 earnings release call ipa will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2024, on thursday, december 14, 2023, at 10:30 am eastern time. the financial results will be issued in a press release prior to the call. investors, analysts, and other stakeholders are invited to participate in the conference call, during which ipa's senior leadership will discuss the financial results and provide insights into the company's performance and future outlook. title: ipa reports financial results and recent business highlights for second quarter fiscal year 2024 event date: december 14, 2023 event time: 10:30 et webcast url: https://events.q4inc.com/attendee/905281713 participant details participant toll-free dial-in number: 1 (888) 550-5658 participant toll dial-in number: 1 (646) 960-0289 conference id: 9236374 about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com source: immunoprecise antibodies ltd. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the future expectations for ipa, including expectations regarding ipa achieving groundbreaking advancements and sustained growth in the industry. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, as discussed in the company’s annual information form dated july 10, 2023 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 10, 2023 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.

victoria, british columbia, june 13, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“ipa” or the “company”), a leader in ai-driven biotherapeutic research and technology, is excited to announce a new use case for the information integration dilemma (iid) solution developed by its subsidiary, biostrand®. link to use case here the iid has long been a significant challenge in the biotechnology industry, with researchers and investors grappling with the complexities of integrating diverse data types to gain meaningful insights. biostrand's lensaitm platform and patented hyft® technology have successfully addressed this issue, providing a unified framework that encapsulates and integrates diverse data modalities, including syntactical (sequence) data, 3d structural data, unstructured scientific information, and more. this breakthrough approach has paved the way for quicker and more potent biological discoveries, and the unveiling of this use case demonstrates the practical application of this technology in the field of biotechnology. this use case provides a detailed look at how hyft technology and the lensai platform can be utilized to solve complex biological problems, offering a glimpse into the future of biotherapeutic research and development. "our newest use case stands as a potent testament to how we've successfully navigated the iid. it demonstrates the power of integrating and organizing heterogeneous data types and reflects depth of insights gleamed using our comprehensive knowledge graph. this graph, teeming with over 25 billion relations, bridges the gap between sequence, structure, and textual data in a manner that was previously inconceivable. the application of these interconnections has unearthed insights and relationships that were otherwise invisible, enhancing our understanding of biological systems.” the unveiling of this use case is a testament to immunoprecise's commitment to innovation and its dedication to solving complex problems in the field of biotechnology. the company continues to lead the way in ai-driven biotherapeutic research and technology, and this latest development further solidifies its position as a pioneer in the industry. about biostrand’s hyft technology biostrand's hyft technology extracts unique patterns, known as universal fingerprint™ patterns, from the entire biosphere, and integrates them with various data sources, such as scientific papers and medical records. the resulting knowledge graph encompasses over 660 million hyfts and more than 25 billion relations, providing a powerful resource for researchers and ai-driven analysis. the lensai platform, powered by hyft technology, takes advantage of the latest advancements in large language models (llms) to bridge the gap between syntax (sequences) and semantics (functions). this enables the platform to extract valuable insights from vast amounts of data, without the limitations of traditional llms. ipa's support of biostrand's pioneering work reinforces its commitment to investing in cutting-edge biotechnology solutions with the potential to transform the industry. about immunoprecise antibodies ltd immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome on the drug development process of the integration of ipa’s lensai in silico humanization platform with its hyft technology, and statements relating to ipa’s expected increased revenue streams and financial growth. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of ipa’s lensai platform with its hyft technology may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

victoria, british columbia may 30, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, today announced that its subsidiary, biostrand®, has successfully solved the information integration dilemma (iid) by developing a unique technology design that enables their patented hyft technology to encapsulate and unify diverse data modalities - including syntactical (sequence) data, 3d structural data, unstructured scientific information (e.g. scientific literature), and beyond - into a singular, integrated framework. this breakthrough approach facilitates efficient data fusion, enabling a comprehensive analysis and interpretation of complex biological data. with hyfts, biostrand effectively addresses the iid, paving the way for quicker and more potent biological discoveries. this innovation has the potential to bring a paradigm shift in various domains including drug development, biomarker discovery, and the study of disease pathology, among others. the iid has long been a significant challenge for the biotechnology industry, as researchers and investors have grappled with the complexities of integrating various data types to gain meaningful insights. in the rapidly evolving field of biotechnology, data is generated from multiple sources such as scientific literature, experimental data, and genomic information. the integration of these different data types is critical for accelerating innovation and driving the discovery of novel therapeutics. however, traditional approaches have struggled to efficiently combine and analyze this diverse data, often leading to incomplete or inaccurate conclusions. biostrand's breakthrough approach leverages its patented hyft® technology and lensaitm platform, which together enable the efficient analysis and understanding of complex biological data. by solving the iid, biostrand has unlocked new possibilities for the discovery and development of novel therapeutics, which is expected to benefit both patients and the investor community. dirk van hyfte, co-founder and head of innovation of biostrand, said, "we are thrilled to have overcome the information integration dilemma, which has long been a major hurdle in our industry. our hyft technology and lensai platform are now poised to revolutionize the way researchers and ai-driven systems process and analyze complex biological data, ultimately leading to faster and more effective drug discovery and development." biostrand's hyft technology extracts unique patterns, known as universal fingerprint™ patterns, from the entire biosphere, and integrates them with various data sources, such as scientific papers and medical records. the resulting knowledge graph encompasses over 660 million hyfts and more than 25 billion relations, providing a powerful resource for researchers and ai-driven analysis. the lensai platform, powered by hyft technology, takes advantage of the latest advancements in large language models (llms) to bridge the gap between syntax (sequences) and semantics (functions). this enables the platform to extract valuable insights from vast amounts of data, without the limitations of traditional llms. ipa's support of biostrand's pioneering work reinforces its commitment to investing in cutting-edge biotechnology solutions with the potential to transform the industry. the successful resolution of the information integration dilemma not only demonstrates the innovative nature of biostrand's technology but also highlights the company's dedication to improving the lives of patients worldwide. about immunoprecise antibodies ltd: immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd., and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modeling, and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of in silico models and wet-lab experiments may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

agreement focuses on in silico and de novo discovery and development of antibodies against tumor microenvironment targets. program will leverage biostrand’s (a talem affiliate) lensᵃⁱ® integrated intelligence technology®, built upon the proprietary hyft index®. victoria, british columbia march 30, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”) an ai-driven biotherapeutic research and technology company today announced a research collaboration and exclusive option license agreement with xyphos biosciences, inc. (a wholly owned subsidiary of astellas pharma inc., “astellas”). under the terms of the agreement, the companies will jointly conduct research activities to identify and optimize proprietary lensᵃⁱ in silico generated antibodies, targeting an undisclosed target in the tumor microenvironment (tme), as potential therapeutic development candidates. targeting this molecule has the potential to markedly enhance anti-tumor immunity with other astellas therapies including chimeric antigen receptor-based (car) technologies. astellas will have the exclusive option to license any development candidates generated as part of the collaboration. ”we are proud to build upon the robust in silico antibody discovery capabilities developed by our team at biostrand. their lensᵃⁱ software and core hyft index are uniquely positioned to analyze targets and design antibodies directed at otherwise challenging oncological proteins, especially those that mediate immune suppression in the tme,” stated dr. jennifer bath, president and ceo of ipa. “third-party due diligence continues to support the industry’s excitement of recent biostrand developments and the potential of lensᵃⁱ to accelerate the discovery of more precise next-generation cancer therapies. we are excited to collaborate with astellas to advance our joint mission of bringing safer and more effective treatments to patients in need.” targeting this molecule in the tme with antibody therapeutics is a novel approach with no antibodies in clinical development. developing next-generation checkpoint inhibitor immunotherapies using new modalities is promising as an innovative healthcare solution. through this collaboration we expect to stimulate a highly specific and targeted attack on cancer cells by optimizing these development candidates and leveraging astellas' flexible convertiblecar™ cell therapy technology. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of in silico models and wet-lab experiments may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

company received official notice from the european patent office (epo) for the decision to grant its patent application on april 5th, 2023. the patent was initially filed february 7th, 2020. patent application covers a method to efficiently handle mass biological sequence information. related patents pending in other countries, favorable outcomes anticipated victoria, british colombia march 27, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), the parent company of biokey and affiliate of biostrand, announced today that the epo has issued a “decision to grant” for biokey’s patent application covering the company’s hyft® technology used to organize and analyze biological sequence information. the hyft technology and methodology provide a novel way to efficiently tap into sequence information, allowing the extraction and use the relevant information therein to address the current problems in omics data integration and analysis. the hyft technology serves as the core of the biostrand’s lensai integrated technologytm platform which provides cutting-edge data solutions and antibody discovery. the patent will provide biostrand’s lensai integrated technology with broad protection, further strengthening the company’s patent portfolio position and enabling exclusive access to the hyft technology. the company anticipates favorable outcomes in other countries as well, as many patent offices worldwide consider the status of related european cases to be highly relevant to the decision to grant patents. “this is a significant and exciting decision by the epo, and we view this announcement as a recognition of biostrand’s important contributions to the fields of omic data integration and analysis, fields paramount to the future of cancer research, precision medicine, biomarker identification, and novel drug discovery and development,” stated dr. jennifer bath, ceo of ipa. “this patent provides protection for biokey’s hyft technology, which will give scientists the ability to advance the development of safer and more effective therapies for the toughest medical challenges we face today.” the hyft technology hyft technology is a way of organizing information about the natural world by creating connections between patterns found in living things, called hyfts. these patterns can link genetic sequences to their structures and functions, as well as to other information such as scientific papers and medical records. the output, the hyft knowledge graph, contains over 660 million patterns and 25 billion connections, and is continuously updated with new information. this provides a powerful tool for exploring relationships in the natural world, which can be used for research and applications in medicine and other fields. the hyft graph is unique in its explicit representation of information from the whole biosphere, and it provides a transparent intermediate layer between sequences and predictions that allows for new knowledge to be extracted without the limitations of a black box. hyft-based technologies have numerous applications in various fields beyond just data integration, organization, and analysis, such as drug immunogenicity testing, drug discovery, and natural language processing (nlp). these applications have the potential to accelerate the drug development process and improve patient outcomes. in the field of immunogenicity, hyfts can help predict parts of a molecule that may trigger an immune response. this information is crucial in therapeutic and vaccine development, as it helps identify potential safety concerns before they become problematic. moreover, hyfts can predict off-target effects, which occur when a drug or therapy affects unintended targets in the body. early identification of potential off-target effects allows researchers to design safer and more effective treatments. in drug discovery, hyft-based technologies have multiple potential applications, including: toxicity prediction: by linking genetic sequences to toxicological data, hyfts can predict the toxicity of potential drug candidates, helping researchers identify compounds likely to cause adverse effects before entering clinical trials. drug repurposing: hyfts can identify existing drugs for repurposing by linking genetic sequences to known targets and functions, accelerating the drug discovery process by finding compounds already approved for other indications. clinical trial design: hyfts can optimize clinical trial design by linking genetic sequences to patient data and clinical outcomes, identifying patient subgroups more likely to benefit from specific treatments, and enabling personalized and efficient clinical trials. biomarker discovery: by linking genetic sequences to disease-specific phenotypes, hyfts can identify biomarkers of disease, helping to identify at-risk patients and enable earlier diagnosis and treatment. another application of hyft-based technologies is tied to nlp, which involves analyzing and extracting information from written or spoken language. hyfts can link text-based information, such as scientific papers or medical records, to specific genetic sequences or structures, facilitating more efficient and accurate analysis. this is particularly valuable in genomics and personalized medicine, where vast amounts of textual data must be processed and analyzed to identify potential therapies or treatments. the company believes that the utilization of hyft-based technologies in drug discovery and other fields shows great promise for expediting the drug development process and enhancing patient outcomes. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, biokey bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the potential applications of hyft-based technologies and the prediction capabilities and speed of the discovery processes. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the integration of the above-mentioned hyfts may not have the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies

the program will leverage biostrand’s lensai® full suite of integrated intelligence technology® with libera bio’s multifunctional polymeric nanocapsules (mpn technology®) the alliance has stipulated a minimum of upfront and downstream milestone payments of usd 155 million plus commercial royalties, per product developed victoria, canada and santiago de compostela, spain, march 15, 2023 – immunoprecise antibodies ltd. (nasdaq: ipa) (“immunoprecise” or “ipa” or the “company”), an ai-driven biotherapeutic research and technology company, today announced that talem therapeutics llc, an independently operating subsidiary of ipa, and libera bio s.l., have signed a collaboration agreement to jointly address intracellular targets. it is estimated that 75% of disease-causing targets are located inside cells1. some of the most elusive cancer targets are expressed inside tumor cells. because they are so difficult to address, they have sometimes been deemed “undruggable” and thus represent high unmet medical needs. numerous pathways intersect inside tumor cells, such as the mapk pathway or the “hedgehog pathway”, and may generate conditions for tumors to develop, grow and evade the immune system. disrupting signals at one or more points within these pathways may slow down the growth of the tumors and inhibit their proliferation. small molecules have been successfully developed to this end, but they often present a significant lack of specificity resulting in toxicity, leading to undesirable side effects for patients. engineering antibodies to force them inside tumor cells has also been attempted, but it is a complex process, often wrought with failure. the collaboration between talem and libera bio will leverage a nanotechnology that has been proven in vivo to deliver antibodies inside tumor cells and provides a potential solution to this medical challenge. libera bio’s multifunctional polymeric nanocapsules (mpn technology®) offer an elegant way to deliver antibodies inside tumor cells. the relevant antibodies are encapsulated in multi-layer nanocapsules of approximately 1/10,000th of a millimeter in diameter. the nanocapsules are specifically designed around the physicochemical properties of antibodies, to protect them from degradation in the blood stream. libera bio believes that this might be the only nanotechnology with in vivo proof of concept of delivering whole antibodies intracellularly. in addition, mpns can deliver other biologic modalities or combinations of a biologic and a small molecule in the same nanocapsule. passively or actively targeted, the mpns deliver these compounds through a cell membrane and to intracellular targets. whole antibodies, close to their natural form, can be delivered in this manner. talem will leverage its antibody discovery and development expertise and access, including without limitation, the lensai technology® from biostrand b.v., an independently operating subsidiary of ipa. biostrand has developed a proprietary, ai-driven platform to optimize the design of such antibodies. biostrand computationally generates and rapidly screens a large set of diverse antibody candidates against a prioritized list of targets, including intracellular targets. talem and libera bio will jointly develop novel antibodies for use with mpn delivery, with the goal of offering them to larger pharma companies to conduct late-stage development and commercialization. the work launches with the investigation of two intracellular targets with very high unmet patient needs to offer options to the oncologists treating them. “as we continue to push the boundaries of cancer therapy, the ability to target intracellular proteins has been the 'holy grail' in oncology. libera bio's ground-breaking approach of enabling biologics to penetrate the cell membrane and reach previously 'undruggable' targets is an exciting development that has the potential to transform the way we treat cancer,” said dr. jennifer bath, ceo and president of immunoprecise antibodies ltd. “the libera bio team has been very impressed with the combination of modern in silico tools and wet lab capabilities at the ipa family of companies. we are looking forward to this alliance that just may yield dozens of new options for cancer treatment,” added olivier jarry, co-founder and ceo of libera bio. 1. verdine gl, walensky ld. the challenge of drugging undruggable targets in cancer: lessons learned from targeting bcl-2 family members. clin cancer res. 2007;13(24):7264-70. doi:10.1158/1078-0432.ccr-07-2184. about immunoprecise antibodies ltd. immunoprecise antibodies ltd. has several subsidiaries in north america and europe including entities such as talem therapeutics llc, biostrand bv, immunoprecise antibodies (canada) ltd. and immunoprecise antibodies (europe) b.v. (collectively, the “ipa family”). the ipa family is a biotherapeutic research and technology group that leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its proprietary technologies in bioplatform-based antibody discovery. services include highly specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners in their quest to discover and develop novel biologics against the most challenging targets. for further information, visit www.ipatherapeutics.com. investor contact: investors@ipatherapeutics.com about libera bio. s.l. libera bio s.l. (www.liberabio.com) is a private spanish company, spun off from the university of santiago de compostela (galicia, spain). libera bio aims at changing cancer therapy by allowing biologics to cross the cell membrane and reach “undruggable” intracellular targets: the “holy grail” in oncology. it has conducted preclinical studies of antibodies addressing frequent mutations of kras, a protein involved in a large number of cancers, particularly pancreatic, colorectal and lung cancers. it is now preparing for the enabling studies aiming at a clinical trial authorization. visit http://liberabio.com contact: olivier jarry, ceo, contact@liberabio.com forward looking information this news release contains forward-looking statements within the meaning of applicable united states securities laws and canadian securities laws. forward-looking statements are often identified by the use of words such as “potential”, “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. forward-looking information contained in this news release includes, but is not limited to, statements regarding the ability to design and to deliver antibodies to address intracellular targets in a safe and effective manner as well as statements relating to the expected outcome of integrating in silico models and wet-lab experiments. in respect of the forward-looking information contained herein, ipa has provided such statements and information in reliance on certain assumptions that management believed to be reasonable at the time. forward-looking information involves known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements stated herein to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. actual results could differ materially from those currently anticipated due to a number of factors and risks, including, without limitation, the risk that the targeted antibodies may be very difficult or impractical to design, develop and deliver, that the integration of in silico models, wet-lab experiments and preclinical studies may not yield the expected results, as well as those risks discussed in the company’s annual information form dated july 28, 2022 (which may be viewed on the company’s profile at www.sedar.com), and the company’s form 40-f, dated july 29, 2022 (which may be viewed on the company’s profile at www.sec.gov). should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance, or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. accordingly, readers should not place undue reliance on forward-looking information contained in this news release. the forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. the company does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law. source immunoprecise antibodies